A

Aardvark Therapeutics Inc
D

AARD

4.81000
USD
-0.27
(-5.32%)
Post Trading·4.77000USD-0.04000(-0.83%)
حجم التداول
10,579
الربح لكل سهم
-4
العائد الربحي
-
P/E
-1
حجم السوق
104,936,812
المقالات
المزيد

العنوان: Aardvark Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which haveinitiated a Phase 3 clinical trial for hyperphagia associated with PWS.